Legal Representation
Attorney
Stephen R. Barrese, Esq.
USPTO Deadlines
Next Deadline
In Grace Period
Section 8 Declaration Due (Principal Register) (Based on registration date 20191008)
Due Date
October 08, 2025
Grace Period Ends
April 08, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 8, 2024 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Oct 8, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 23, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 23, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 3, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 19, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 17, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 17, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 13, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 7, 2019 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Mar 29, 2019 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 29, 2019 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 29, 2019 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Mar 29, 2019 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Mar 29, 2019 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 29, 2019 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 29, 2019 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 26, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 18, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 2, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for medical use, namely, pharmaceutical preparations for immunoregulation, for treatment of autoimmune diseases, for use as anti-cancer agents, for treatment of cancer, for treatment of tumors, for treatment of central nervous system disorders and for treatment of metabolic diseases; pharmaceutical preparations for treating human immune diseases and conditions; pharmaceutical preparations for treating inflammatory diseases and conditions; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating rheumatoid arthritis; pharmaceutical preparations for treating psoriatic arthritis; pharmaceutical preparations for treating ankylosing spondylitis; pharmaceutical preparations for treating psoriasis; pharmaceutical preparations for treating polyarticular juvenile idiopathic arthritis; pharmaceutical preparations for treating enthesitis-related arthritis
Classification
International Classes
005